What inherited cancer predisposition syndrome is suggested by a family history of uveal melanoma with brain metastasis at age 50 and HER2‑positive breast cancer in relatives at ages 55 and 65, and what genetic testing and surveillance are recommended?

Suspected BAP1 Tumor Predisposition Syndrome

This family history strongly suggests BAP1 tumor predisposition syndrome, and genetic testing for germline BAP1 mutations should be pursued immediately, with consideration for broader multi-gene panel testing if BAP1 is negative.

Why BAP1 Syndrome is the Leading Diagnosis

The constellation of uveal melanoma (eye cancer) with brain metastases plus multiple cases of breast cancer in this family is highly characteristic of BAP1 tumor predisposition syndrome 1. While Li-Fraumeni syndrome (TP53 mutations) classically includes brain tumors and premenopausal breast cancer 2, the presence of uveal melanoma is pathognomonic for BAP1 syndrome and distinguishes this from other hereditary cancer syndromes 1.

Key Clinical Features Supporting BAP1:

• Uveal melanoma is the hallmark cancer of BAP1 syndrome 1
• The syndrome includes predisposition to:
  • Uveal melanoma
  • Cutaneous melanoma
  • Renal cell carcinoma
  • Mesothelioma
  • Breast carcinoma (increasingly recognized as part of the phenotype) 1
  • Cholangiocarcinoma and other internal malignancies 1

Alternative Diagnostic Considerations

Why Not Li-Fraumeni Syndrome?

While historical case reports from 1905 and 1993 described families with uveal melanoma and breast cancer as possible Li-Fraumeni syndrome 3, modern molecular understanding has clarified that uveal melanoma is NOT a core Li-Fraumeni cancer. The classic LFS spectrum includes: soft tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumors, and adrenocortical carcinoma 2. The 2024 ASCO guidelines list TP53 testing only for patients under age 30 with specific tumor types, and recommend caution testing TP53 in breast cancer patients over age 45 without suspicious family history due to CHIP (clonal hematopoiesis) concerns 4.

BRCA2 Consideration

BRCA2 mutations have been reported in some uveal melanoma families with breast/ovarian cancer 5, 6, but this accounts for only a small proportion of cases. The relative diagnosed at age 50 with uveal melanoma makes BRCA2 less likely as the primary driver, though it remains a differential.

Other Candidate Genes

Recent whole exome sequencing studies identified pathogenic variants in PALB2, MLH1, MSH6, CHEK2, and other genes in UM patients with strong cancer histories 7. However, BAP1 remains the most established and highest-penetrance gene for uveal melanoma predisposition 1.

Recommended Genetic Testing Strategy

Per 2024 ASCO guidelines 4, multi-gene panel testing is appropriate for patients with personal or family histories suggesting hereditary cancer:

1. First-line testing: BAP1 germline sequencing and deletion/duplication analysis
2. If BAP1 negative: Expanded panel including:
   • BRCA1/BRCA2 (given multiple breast cancers)
   • PALB2, CHEK2, ATM (moderate-penetrance breast cancer genes with emerging UM associations) 7
   • TP53 (only if ages at diagnosis support LFS criteria)
   • Consider MLH1, MSH6 if any colorectal/endometrial cancers in family 7

Surveillance and Management Implications

If BAP1 Mutation Confirmed:

Cancer surveillance should include:

• Annual dermatologic examination for cutaneous melanoma and BAP1-associated skin lesions
• Annual ophthalmologic examination with dilated fundoscopy for uveal melanoma
• Consider annual MRI abdomen/pelvis for renal cell carcinoma (protocols still evolving)
• Breast cancer screening per high-risk protocols (annual MRI + mammography starting age 30-35)
• Low-threshold for chest imaging if respiratory symptoms (mesothelioma risk)

For HER2+ Breast Cancer Relatives:

The HER2-positive status is likely coincidental to the germline predisposition rather than a defining feature. However, if either relative develops brain metastases, trastuzumab deruxtecan (T-DXd) has demonstrated exceptional CNS activity with intracranial response rates of 62-82% and CNS PFS of 17.3 months 8, 9, potentially obviating or delaying radiotherapy.

Critical Pitfalls to Avoid

• Don't dismiss uveal melanoma as unrelated: This is the key diagnostic clue that distinguishes BAP1 from more common syndromes
• Don't limit testing to BRCA1/2: The 2024 ASCO guidelines emphasize multi-gene panels for complex family histories 4
• Don't test TP53 in isolation: Given the ages at diagnosis (50,55,65), TP53 is less likely and risks identifying CHIP variants 4
• Don't forget cascade testing: All first-degree relatives of a mutation carrier should be offered predictive testing

Testing Logistics

Genetic counseling should precede testing to discuss implications for the entire family. Testing can be ordered through any CLIA-certified laboratory offering hereditary cancer panels. Insurance typically covers testing when clinical criteria are met (multiple affected relatives with syndrome-associated cancers).